ClinicalTrials.gg
CompletedNCT05630573Updated Jun 28, 2024

A Study of TNM001 in Chinese Healthy Preterm and Term Infants

A Phase 1/2 interventional study of TNM001 and Placebo in Respiratory Syncytial Virus Infections, sponsored by Zhuhai Trinomab Pharmaceutical Co., Ltd.. Completed at 6 sites in China. Open to participants aged Up to 1 Year, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-06-28.

Sponsored by Zhuhai Trinomab Pharmaceutical Co., Ltd. · Phase 1/2, Interventional, and Prevention

From the registry’s dates

  • Primary completion was Jun 2023, 3 years 4 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Jun 2024.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
31
Allocation
Randomized
Ages
Up to 1 Year
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies in Respiratory Syncytial Virus Infections with a site in China — 8 open to participants now, 13 under way, 4 of them phase 3. Respiratory Syncytial Virus Infections · China.

Enrollment
19th of 25
31 · median 132
Started
2022
with 2 others
Phase 1/2
3 of 30
1 open now
Registered
5th of 30
by date
Lead sponsor
3 of 30
Zhuhai Trinomab Pharmaceutical Co., Ltd.

Among the 30 studies in Respiratory Syncytial Virus Infections with a site in China, this one is the 19th largest by enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2022, is one of 3 in phase 1/2, and was the 5th registered.

Respiratory Syncytial Virus Infections

306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.

Browse Respiratory Syncytial Virus Infections studies →

Open to participants now

8 of the 30 studies in Respiratory Syncytial Virus Infections with a site in China are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.

This study: Up to 1 Year · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Respiratory Syncytial Virus Infections with a site in China, or all of them as a file.
02

Study summary

The purpose of this clinical trial is to evaluate the safety, tolerability and pharmacokinetics (PK) profile of TNM001 injection in healthy preterm and term infants. The main questions it aims to answer are:

  • the safety and tolerability of TNM001 injection
  • the pharmacokinetic (PK) profile of TNM001
Read the detailed description

This phase Ib/IIa study is designed to assess the safety, tolerability, and pharmacokinetics (PK) profile TNM001 in healthy preterm and term infants. This study will also compare the incidence of Respiratory Syncytial Virus(RSV) infection between different doses of TNM001 and placebo, which will be used to select the dose to be studied in the later phase of clinical trials of TNM001. Approximately 30 subjects will be randomized and will be dosed once on Day 1 and followed up until Day 151. Around 6 investigational study centres participate in the study.

03

Conditions studied

  • Respiratory Syncytial Virus Infections
04

Who can participate

Ages eligible
Up to 1 Year
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  1. Healthy preterm infants and term infants within 1 year old of age
  2. Infants who are in the first RSV infection season at the time of randomization

Key Exclusion Criteria:

  1. Any fever or acute illness within 7 days prior to dosing
  2. LRTI prior to randomization
  3. Received any anti-RSV monoclonal antibody or RSV vaccine
  4. Any other circumstances that, in the opinion of the investigator, may interfere with the assessment of the study drug or the interpretation of the study results
  5. The subject is a child of the investigator or his/her subordinate study personnel or relatives or sponsor staff
05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    TNM001 Injection dose 1

    low dose administered

    Biological: TNM001

  • Experimental
    TNM001 Injection dose 2

    medium dose administered

    Biological: TNM001

  • Experimental
    TNM001 Injection dose 3

    high dose administered

    Biological: TNM001

  • Placebo comparator
    placebo

    placebo administered

    Biological: Placebo

Interventions

  • BiologicalTNM001

    intramuscular injection

  • BiologicalPlacebo

    intramuscular injection

06

What researchers measure

Primary outcomes

  1. Safety and tolerability of TNM001 Injection

    Type and incidence of adverse events and serious adverse events

    Time frame: 150 days post dose

Secondary outcomes

  1. Area Under the Concentration-Time Curve From Zero to Infinity (AUC [0-infinity]) of TNM001

    The pharmacokinetic (PK) parameter AUC (0-infinity) will be estimated based on the serum concentrations of TNM001

    Time frame: 150 days post dose

  2. Maximum Observed Serum Concentration (Cmax) of TNM001

    The Cmax is the maximum observed serum concentration of TNM001

    Time frame: 150 days post dose

  3. Terminal Elimination Half Life (t1/2) of TNM001

    Terminal phase elimination half-life (t1/2) is the time required for half of the drug to be eliminated from the serum

    Time frame: 150 days post dose

  4. Serum anti-RSV neutralizing antibodies titer levels in each dose cohort

    To summarize the proportion of subjects with severalfold increase after dosing compared to the predose (baseline)

    Time frame: 150 days post dose

  5. Anti-drug antibody (ADA) positive rate of TNM001

    The evaluation indicator of immunogenicity is the ADA positive rate in subjects

    Time frame: 150 days post dose

Other outcomes

  1. Lower respiratory tract infection(LRTI)

    The incidence of LRTI

    Time frame: 150 days post dose

07

Study locations

6 sites
  • The Second Hospital of Hebei Medical University
    Shijiazhuang, Hebei 050000, China
  • Hunan Provincial People's Hospital
    Changsha, Hunan 410005, China
  • The Third Xiangya Hospital of Central South University
    Changsha, Hunan 410006, China
  • Linfen People's Hospital
    Linfen, Shanxi 041000, China
  • Yuncheng Central Hospital
    Yuncheng, Shanxi 044099, China
  • West China Second University Hospital, Sichuan University
    Chengdu, Sichuan 610041, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2022 to primary completion in Jun 2023, 8 months.

Of 16 phase 1/2 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 27. This study's 8 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2022
First posted
Nov 29, 2022
StartActual
Oct 25, 2022
Primary completionActual
Jun 30, 2023
CompletionActual
Jun 30, 2023
Results delay requested
Jun 19, 2024
Last update
Jun 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05630573
Lead sponsor
Zhuhai Trinomab Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Nov 29, 2022
Start date
Oct 25, 2022
Primary completion
Jun 30, 2023
Completion
Jun 30, 2023
Last update
Jun 28, 2024

Study contacts

Hanmin Liu
principal investigator · West China Second Hospital, Sichuan University
Qin Yu
principal investigator · West China Second Hospital, Sichuan University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Retavibart

Start the discussion